FOXO Technologies (FOXO Technologies) Risk Assessment

View and export this data going back to 2022. Start your Free Trial

What is FOXO Technologies Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of FOXO Technologies is: No Data: Cannot be evaluated.

Competitive Comparison of FOXO Technologies's Risk Assessment

For the Health Information Services subindustry, FOXO Technologies's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

FOXO Technologies's Risk Assessment Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, FOXO Technologies's Risk Assessment distribution charts can be found below:

* The bar in red indicates where FOXO Technologies's Risk Assessment falls into.

FOXO Technologies (AMEX:FOXO) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

FOXO Technologies Risk Assessment Related Terms

Thank you for viewing the detailed overview of FOXO Technologies's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

FOXO Technologies (FOXO Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » FOXO Technologies Inc (AMEX:FOXO) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

729 Washington Avenue N, Suite 600, Minneapolis, MN, USA, 55401

Website

https://www.foxolife.com

FOXO Technologies Inc is a technology platform company focused on commercializing longevity science through products and services that serve the life insurance industry. FOXO's epigenetic technology applies AI to DNA methylation to identify molecular biomarkers of human health and aging.

Executives

Martin Christopher Ward	officer: Interim CFO	CHALKSTREAM, KINGS SOMBORNE, STOCKBRIDGE X0 S020 6NZ
Mark Brian White	director, officer: Interim CEO	IMMEUBLE MILA, CHAMPERY V8 1874
Dowling Vincent J. Jr	10 percent owner	54 LEDYARD, WEST HARTFORD CT 06117
Gwg Holdings, Inc.	10 percent owner	325 N. ST. PAUL STREET, SUITE 2650, DALLAS TX 75201
Taylor Fay	officer: Chief Operating Officer	729 N. WASHINGTON AVE, SUITE 600, MINNEAPOLIS MN 55401
Jon Sabes	director, 10 percent owner, officer: CEO, Chairman	701 NORTH THIRD STREET, MINNEAPOLIS MN 55401
Bret Barnes	director	220 SOUTH SIXTH STREET, MINNEAPOLIS MN 55402
Brian Chen	officer: Chief Science Officer	220 SOUTH SIXTH STREET, SUITE 1200, MINNEAPOLIS MN 55402
Erin Sharoni	officer: Chief Product Officer	220 SOUTH SIXTH STREET, SUITE 1200, MINNEAPOLIS MN 55402
Michael Will	officer: General Counsel	220 SOUTH SIXTH STREET, SUITE 1200, MINNEAPOLIS MN 55402
Tyler Danielson	officer: Chief Technology Officer	220 SOUTH SIXTH STREET, SUITE 1200, MINNEAPOLIS MN 55402
Murdoc Khaleghi	director	220 SOUTH SIXTH STREET, SUITE 1200, MINNEAPOLIS MN 55402
Robert Potashnick	officer: Chief Financial Officer	220 SOUTH SIXTH STREET, SUITE 1200, MINNEAPOLIS MN 55402
Plc Barclays	10 percent owner	1 CHURCHILL PLACE, CANARY WHARF, LONDON X0 E14 5HP
Paul Britton Newhouse	director	ONE CITY CENTRE, 1021 MAIN STREET SUITE 1960, HOUSTON TX 77002

FOXO Technologies (FOXO Technologies) Headlines

From GuruFocus

Thinking about buying stock in AMC Entertainment, Evolve Transition Infrastructure, Silicom, Foxo Technologies, or Yellow?

By PRNewswire • 08-02-2023